A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer - Pivot, X B; Bondarenko, I; Dvorkin, M (J Clin Oncol, 2017)